AIM ImmunoTech (NYSE:AIM – Free Report) had its target price lowered by Ascendiant Capital Markets from $5.25 to $5.00 in a report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.
AIM ImmunoTech Stock Performance
NYSE:AIM opened at $0.34 on Tuesday. The stock has a market cap of $19.47 million, a price-to-earnings ratio of -0.53 and a beta of -0.35. The business’s 50-day simple moving average is $0.35 and its 200 day simple moving average is $0.39. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.17. AIM ImmunoTech has a one year low of $0.25 and a one year high of $0.68.
AIM ImmunoTech (NYSE:AIM – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%.
Institutional Trading of AIM ImmunoTech
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than AIM ImmunoTech
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Small Cap Stocks That Insiders Are Buying
- There Are Different Types of Stock To Invest In
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- 5 Top Rated Dividend Stocks to Consider
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.